Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790693 | 0.91 | RAF1 (0.47) | SLC2A1CYP11B1CYP11B2CYP19A1ALDH1A1 | |
| SCHEMBL3798711 | 0.90 | FHIT (0.45) | CYP11B1ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL3786449 | 0.85 | CYP11B1 (0.48) | CYP11B1CYP19A1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3791788 | 0.80 | FHIT (0.45) | CYP11B1ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL3797311 | 0.77 | MAPK14 (0.44) | CYP11B1CYP11B2CYP19A1ALDH1A1HPGD | |
| SCHEMBL3790745 | 0.76 | CYP11B1 (0.48) | CYP11B1CYP19A1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3791710 | 0.75 | CYP11B1 (0.44) | CYP11B1CYP19A1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3794517 | 0.75 | NPY5R (0.47) | CYP11B1CYP19A1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3786530 | 0.75 | CYP11B1 (0.49) | CYP11B1ALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL3791749 | 0.74 | FHIT (0.48) | CYP11B1ALDH1A1HPGDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| CN-101326181-A | Imidazopyridine derivatives as a2b adenosine receptor antagonists | ALMIRALL LAB (ES) | 2008-12-17 | — | — | CN | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| WO-2007039297-A1 | IMIDAZOPYRIDINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | SLC2A1 240/4885CYP11B1 327/4885CYP11B2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.